Abstract:Background: Emerging evidence shows that coronavirus disease 2019 (COVID-19) is commonly complicated by coagulopathy, and venous thromboembolism (VTE) is considered to be a potential cause of unexplained death. Information on the incidence of VTE in COVID-19 patients, however, remains unclear.Method: English-language databases (PubMed, Embase, Cochrane), Chinese-language databases (CNKI, VIP, WANFANG), and preprint platforms were searched to identify studies with data of VTE occurrence in hospitalized COVID-19 patients. Pooled incidence and relative risks (RRs) of VTE were estimated by a random-effects model. Variations were examined based on clinical manifestations of VTE (pulmonary embolism-PE and deep vein thrombosis-DVT), disease severity (severe patients and non-severe patients), and rate of pharmacologic thromboprophylaxis (≥60 and <60%). Sensitivity analyses were conducted to strengthen the robustness of results. Meta-regression was performed to explore the risk factors associated with VTE in COVID-19 patients.Results: A total of 17 studies involving 1,913 hospitalized COVID-19 patients were included. The pooled incidence of VTE was 25% (95% CI, 19–31%; I2, 95.7%), with a significant difference between the incidence of PE (19%; 95% CI, 13–25%; I2, 93.2%) and DVT (7%; 95% CI, 4–10%; I2, 88.3%; Pinteraction < 0.001). Higher incidence was observed in severe COVID-19 patients (35%; 95 CI%, 25–44%; I2, 92.4%) than that in non-severe patients (6%; 95 CI%, 3–10%; I2, 62.2%; Pinteraction < 0.001). The high rate of pharmacologic thromboprophylaxis in COVID-19 patients (≥60%) was associated with a lower incidence of VTE compared with the low pharmacologic thromboprophylaxis rate (<60%) (19 vs. 40%; Pinteraction = 0.052). Severe patients had a 3.76-fold increased risk of VTE compared with non-severe patients (RR, 4.76; 95% CI, 2.66–8.50; I2, 47.0%). Sensitivity analyses confirmed the robustness of the primacy results.Conclusions: This meta-analysis revealed that the estimated VTE incidence was 25% in hospitalized COVID-19 patients. Higher incidence of VTE was observed in COVID-19 patients with a severe condition or with a low rate of pharmacologic thromboprophylaxis. Assessment of VTE risk is strongly recommended in COVID-19 patients, and effective measures of thromboprophylaxis should be taken in a timely manner for patients with high risk of VTE.

Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines

Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019

Hemorrhage and Venous Thromboembolism in Critically Ill Patients with COVID-19

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic

2023 Chinese Expert Consensus on the Impact of COVID-19 on the Management of Cardiovascular Diseases

Anticoagulation for COVID-19 Patients: A Bird's-Eye View

COVID-19 and Venous Thromboembolism: From Pathological Mechanisms to Clinical Management

Coronavirus Disease 2019 Combined with Venous Thromboembolism:Clinical Features and Prevention

Venous Thromboembolism Prevention in COVID-19: A Review of Latest Evidences

Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis

Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum

A systematic review and meta-analysis of incidence, prognosis, and laboratory indicators of venous thromboembolism in hospitalized patients with coronavirus disease 2019

COVID-19 related thrombosis: A mini-review

Risk Assessment of Venous Thromboembolism and Bleeding in COVID-19 Patients.

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

Venous Thromboembolic Events in Patients with COVID-19: a Systematic Review and Meta-Analysis

Effect of anticoagulation on the incidence of venous thromboembolism, major bleeding, and mortality among hospitalized COVID-19 patients: an updated meta-analysis

Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19

Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19

Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019